Free Trial

CVRx Q2 2024 Earnings Report

CVRx logo
$11.56 +0.26 (+2.30%)
As of 03/11/2025 04:00 PM Eastern

CVRx EPS Results

Actual EPS
-$0.65
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.14
One Year Ago EPS
-$0.56

CVRx Revenue Results

Actual Revenue
$11.81 million
Expected Revenue
$11.84 million
Beat/Miss
Missed by -$30.00 thousand
YoY Revenue Growth
N/A

CVRx Announcement Details

Quarter
Q2 2024
Time
After Market Closes

Conference Call Resources

Conference Call Audio

Remove Ads

CVRx Earnings Headlines

A market crash is coming—here’s when
The stock market cycle I've used to identify the most likely day of the next market crash is the exact same indicator that helped me call the bear market of 2018... the bull market in 2020... the bear market in 2022... the roaring bull markets in 2023 and 2024... and more. I'm convinced it has helped me identify the next big crash too. We are at an important juncture in the markets. Knowing what to do in the months to come is critical.
CVRx Full Year 2024 Earnings: EPS Misses Expectations
See More CVRx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CVRx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CVRx and other key companies, straight to your email.

About CVRx

CVRx (NASDAQ:CVRX), a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

View CVRx Profile

More Earnings Resources from MarketBeat